The efficacy and role of pemetinib/pemetinib and its applicable groups

Pemigatinib is an oral small molecule inhibitor targeting fibroblast growth factor receptor (FGFR) abnormalities. It mainly inhibits the growth and spread of tumor cells by inhibiting the activity of FGFR1, FGFR2 and FGFR3 and blocking downstream signaling pathways. The drug, originally developed by Incyte, has been approved in multiple countries to treat malignant tumors driven by certain genetic changes. The birth of pemetinib represents an important breakthrough in precision medicine in the treatment of solid tumors and hematological tumors, especially for a small number of patients with specific FGFR gene rearrangements, providing new treatment hope.

In the field of cholangiocarcinoma (CCA), pemetinib is specifically targeted at adult patients with FGFR2 fusions or other rearrangements confirmed by genetic testing, especially those with locally advanced or metastatic disease that is unresectable and whose disease has progressed after at least one systemic treatment. Cholangiocarcinoma itself is a highly aggressive malignant tumor with poor prognosis. Traditional chemotherapy (such as gemcitabine combined with cisplatin) has limited efficacy and high recurrence rate. Studies have shown that approximately 10% to 16% of patients with cholangiocarcinoma have FGFR2 fusions or rearrangements, and this subgroup of patients has shown significant clinical benefit from pemetinib. According to the results of clinical trials (such as the FIGHT-202 study), the objective response rate (ORR) of pemetinib in treating such patients is as high as 36%, and some patients even achieved long-term disease control, making this precise targeting regimen an important option after standard treatment.

In addition, pemetinib has also received Breakthrough Therapy designation from the U.S. FDA for the treatment of adult patients with relapsed or refractory myeloid/lymphoid neoplasms (MLN) associated with FGFR1 rearrangements. This disease is a group of rare and highly aggressive hematological malignancies characterized by abnormal rearrangements of the FGFR1 gene, leading to manifestations such as leukemia, myelofibrosis, or lymphoproliferative disorders. Traditional treatments mostly rely on chemotherapy or allogeneic hematopoietic stem cell transplantation, but transplantation is not suitable for all patients, and the treatment window is narrow. Pemetinib is highly targeted and can effectively induce differentiation and control disease progression. Clinical data show that many patients experienced hematological remission and significant reduction in disease burden after receiving pemetinib treatment, bringing substantial improvements in survival to patients with refractory MLN.

From the perspective of pharmacological properties, pemetinib can effectively penetrate the cell membrane, target and inhibit FGFR receptor activity, and prevent the abnormal activation of multiple downstream pathways involved in the FGFR signaling axis (such as the RAS/MAPK, PI3K/AKT pathway), thereby inhibiting cell proliferation and promoting apoptosis. The drug is usually taken orally once a day, with a cycle of three weeks on and one week off to balance efficacy and tolerability. During use, patients need to closely monitor serum phosphate levels because pemetinib can cause hyperphosphatemia, which is one of its more common and manageable side effects. In addition, ocular adverse reactions (such as retinal pigment epithelial detachment), nail discoloration, stomatitis, diarrhea, fatigue, etc. are also common, so regular eye examinations and symptom management are required.

It should be noted that the prerequisite for the use of pemetinib is that patients must pass a certified companion diagnostic test (Companion Diagnostic Testing) to confirm the presence of FGFR2 or FGFR1 rearrangements or fusions. This precise screening strategy not only maximizes treatment effectiveness, but also avoids unnecessary side effect exposure. With the in-depth understanding of tumor molecular mechanisms and the popularization of genetic testing technology, pemetinib may expand its indications in more FGFR-related tumors in the future.

Reference materials:https://go.drugbank.com/drugs/DB15102